Angel Investment: KOA Labs • Andy Palmer

Directed Evolution

What determines which innovations survive - and which simply consume capital?

Andy Palmer, entrepreneur, operator, and investor at ⁠Koa Labs⁠, joins Nic Encina to examine the human and organizational forces that drive meaningful innovation.

From identifying resilient founders and empowering rule-breakers inside large companies to ⁠applying AI in healthcare and education⁠, Andy argues that the next frontier isn't better technology alone. It's ⁠putting existing capabilities to work against real human problems⁠.

In this episode:

  • Why entrepreneurial resilience is scarcer than venture capital.

  • How consensus can suppress breakthrough innovation.

  • Why ⁠AI's hardest challenge is human adoption, not better models⁠.

  • How incentives shape behavior and determine system outcomes.

  • Why transforming entire systems can create more impact than building isolated solutions.

The UnNatural Signal: When technology becomes abundant, the ability to apply it to human needs becomes the differentiator.

Because progress isn't just about what we can build. It's about what we can change.

Some relationships transcend the organizations and projects that first brought us together.

Andy Palmer and I first met in 2005, when we worked together at Infinity Pharmaceuticals. More than 20 years later, we've collaborated on many fronts, navigated different chapters of our careers, and, most importantly, remained close friends.

Andy has been a mentor, a sounding board, and a trusted friend throughout that journey. His perspective and generosity have meant a great deal to me over the years.

It was especially meaningful to sit down with him for unNatural Selection – not just to explore his remarkable perspective on entrepreneurship and innovation, but to share a conversation with someone who has been part of my own journey for so long.

Nic Encina

Global Leader in Precision Health & Digital Innovation • Founder of World-Renown Newborn Sequencing Consortium • Harvard School of Public Health Chief Science & Technology Officer • Pioneer in Digital Health Startups & Fortune 500 Innovation Labs

https://www.linkedin.com/in/encina
Next
Next

Corporate Inertia: Elsevier • Hans Gieskes